Strategy
Commercialization architecture
Building rare-disease and specialty-care businesses from market entry to launch execution, with the operating model shaped before major fixed investment.
About Chad / ZBRA
Rare-disease market entry needs connected commercial judgment.
ZBRA helps foreign biotech and specialty-care companies clarify the access, evidence, stakeholder, partner, and lean-execution requirements that shape Korea and APAC entry decisions.
Chad (ChangDeok) Ji
ZBRA Pharma Consulting
Commercialization and market-access judgment for rare-disease and specialty-care companies entering Korea and APAC.
What I do
Three ways I help companies enter Korea and APAC
Market access
Korea/APAC market-access judgment
Pricing, reimbursement, risk-sharing arrangements, real-world evidence, stakeholder alignment, and launch sequencing.
Execution
Lean execution model
Fractional leadership, partner orchestration, and virtual-subsidiary thinking for companies not ready to build a full local organization.
Proof points
A track record in rare-disease commercialization
Two decades building and launching rare-disease and specialty-care products across Korea and APAC.
20+ years in pharma commercialization.
Rare and specialty launch experience, including an achondroplasia first-in-class pricing and reimbursement approval in about 18 months.
ZBRA at zbrapharma.com.